Registry Overview
Eli Lilly and company, the manufacturer of Cymbalta, has established a voluntary
Pregnancy Registry to learn more information about pregnant women who have taken
Cymbalta during pregnancy, the outcome of the pregnancies, and their babies. The
primary goal of this Pregnancy Registry is to estimate the risk of major birth defects
and other adverse pregnancy outcomes among pregnancies exposed to Cymbalta. Information
gathered in this registry may supplement other sources of data and assist clinicians
and patients in weighing the risks and/or benefits of being treated with Cymbalta
around the time of conception and during pregnancy.
This drug is not approved for use during pregnancy. Cymbalta should be used
during pregnancy only if the potential benefit justifies the potential risk to the
fetus. Because the safety of Cymbalta in infants is not known, nursing while on
Cymbalta is not recommended. Women should notify their doctor if they become pregnant,
plan to become pregnant, or are breastfeeding during Cymbalta therapy.
Cymbalta is not provided by the Registry. Due to the observational nature of this
registry, participation in the Registry will not influence or interfere with the
treatment plan recommended by the patient's health care provider.
The success of the Registry depends on the continued participation of healthcare
providers and pregnant women who have been treated with Cymbalta. Thank you for
your time and participation.
Eligibility and Enrollment
- You must be at least 18 years old, a U.S. resident, pregnant, and have been treated
with Cymbalta during pregnancy.
- The patient or health care provider must contact the Registry to initiate enrollment
(Contact Us).
- Enrollment is voluntary and patients must provide consent. We encourage patients
to enroll as early as possible.
- Patients should click on the
Patient
link for details on their Registry participation.
- Healthcare Providers should click on the
Healthcare Providers
link for details on Registry participation.
Contact Information
This Registry is sponsored by Eli Lilly and Company and is managed by INC Research.
Women who are interested in enrolling or would like additional information should
click on the
Contact Us
link.
For general information about Cymbalta, please refer to following links located
on each site page:
Prescribing Information
,
Safety Information and Boxed Warning,
Medication Guide,
Product Infomation.